Danaher Q4 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Earnings Beat: Danaher reported a Q4 non-GAAP EPS of $2.23, exceeding expectations by $0.04, which underscores the company's robust profitability and enhances investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $6.84 billion, a 5.2% year-over-year increase that surpassed expectations by $30 million, reflecting strong performance in biotechnology and life sciences, driving overall results.
- Future Sales Forecast: Core sales growth for 2026 is projected to remain in the low single digits, with biotechnology expected to grow around 6.0%, indicating sustained growth potential in key areas despite flat performance in others.
- Net Earnings Outlook: Adjusted diluted net earnings per share for 2026 are forecasted to be between $8.35 and $8.50, demonstrating the company's confidence in future profitability while providing clear earnings guidance for investors.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 261.57 USD with a low forecast of 235.00 USD and a high forecast of 310.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 236.710
Low
235.00
Averages
261.57
High
310.00
Current: 236.710
Low
235.00
Averages
261.57
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
